Aging, Exercise, and Hormonal Influences of Fat Metabolism

January 20, 2009 updated by: US Department of Veterans Affairs
The purpose of this study is to determine whether exercise alters the way in which the body stores and breaks down fat. A second objective is to evaluate how these effects are influenced by your age and gender. These studies are important because aging, male gender, and menopause are associated with an increased storage of abdominal fat which is frequently accompanied by diabetes, a high blood cholesterol level, high blood pressure and greater risks of heart attack, stroke, and death. Increasing evidence suggests that these abnormalities and many other effects of aging may be partly due to lack of exercise.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The physiologic cause(s) of the age-related increase in total body and abdominal fat mass are not well-understood. The purpose of this study is to determine whether aging is associated with decreased whole body lipolytic and other metabolic responses to epinephrine and insulin, whether these responses may be augmented by exercise training or in older women by estrogen administration and to investigate whether such metabolic changes are related to reductions in abdominal adiposity. Our objectives in this project are as follows: (1) to characterize age and gender differences in lipolysis and other aspects of metabolism at rest and during graded dose epinephrine infusion with or without a pancreatic islet clamp in healthy non-obese men and women aged 20-40 and 55-75 years, (2) to evaluate relationships between metabolic responses to epinephrine or insulin and portally and nonportally-drained visceral and subcutaneous adipose tissue mass in these individuals, (3) to delineate the effects of acute and chronic exercise on lipolytic and other metabolic responses to epinephrine and insulin and on adipose tissue distribution in healthy younger and older men and women, and (4) to investigate whether 7 days and 12 months or estrogen and cyclic progesterone replacement therapy or placebo in healthy 55-75 year old women alter lipolytic and other metabolic responses to epinephrine and insulin and adipose tissue distribution.

The rates of lipolysis, oxygen uptake, fat and carbohydrate oxidation, and total triglyceride-free fatty acid (FFA) substrate cycling will be determined by indirect calorimetry and by gas chromatography-mass spectrometric analyses of blood samples obtained during infusions of the stable isotope tracers [D5] glycerol and [1 -13C] palmitate in the baseline state, during a pancreatic islet clamp in half of all male and female participants, and in all participants during a subsequent 4-stage graded dose epinephrine infusion. These data will be expressed in relation to total body wieght, fat mass, and fat-free mass, assessed from measurements of body density made by hydrostatic weighing. Adipose tissue distribution will be characterized by determination of the cross-sectional area and volume of portally and nonportally-drained visceral and subcutaneous fat deposits identified by radiographic density criteria on computed tomographic scans obtained at the level of the nipple, umbilicus, gluteal region, and midthigh. Insulin action on glucose disposal will be assessed during a hyperinsulinemic euglycemic clamp. Age and gender differences and their interactions with exercise and the plasma epinephrine concentration in the baseline state and during submaximally and maximally stimulating rates of epinephrine infustion will be evaluated by analysis of variance and covariance. Relationships between effects of estrogen treatment or exercise of adipose tissue distribution and responses to epinephrine and insulin will be assessed by multiple regression analysis.

We hypothesize that increased age will be associated with lower epinephrine-induced rates of lipolysis, fat oxidation, and triglyceride-FFA substrate cycling and decreased insulin action in both men and women when expressed in relation to total fat mass. We further hypothesize that these age-related differences will be at least partly ameliorated by exercise training and by treatment with estrogen in conjunction with a decrease in visceral abdominal and total body adiposity.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • St. Louis, Missouri, United States, 63125
        • VA Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

  • Healthy men or women between the ages of 20 and 75

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 1994

Study Completion

June 1, 2001

Study Registration Dates

First Submitted

December 30, 2004

First Submitted That Met QC Criteria

December 30, 2004

First Posted (Estimate)

December 31, 2004

Study Record Updates

Last Update Posted (Estimate)

January 21, 2009

Last Update Submitted That Met QC Criteria

January 20, 2009

Last Verified

December 1, 2004

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ENDO-050-95S

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Clinical Trials on exercise

Subscribe